Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors (Q34374336)
Jump to navigation
Jump to search
scientific article published on November 24, 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors |
scientific article published on November 24, 2010 |
Statements
1 reference
Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors (English)
1 reference
Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors (English)
1 reference
Jaime A. Davidson
24 November 2010
1 reference
1 reference
1 reference
85
1 reference
12 Suppl
1 reference
S27-37
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference